Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
25
SNTI Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-1.69%
Day range:
$1.10 - $1.16
52-week range:
$1.04 - $5.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.27x
P/B ratio:
3.59x
Volume:
271.2K
Avg. volume:
3.1M
1-year change:
-71.54%
Market cap:
$29.2M
Revenue:
--
EPS (TTM):
-$3.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
-- | -$0.53 | -- | -29.56% | $11.50 |
|
IBIO
iBio, Inc.
|
$25K | -$0.06 | -87.5% | -88.5% | $4.77 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
|
VOR
Vor Biopharma, Inc.
|
-- | -$1.00 | -- | -282.69% | $44.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
$1.11 | $11.50 | $29.2M | -- | $0.00 | 0% | 3.27x |
|
IBIO
iBio, Inc.
|
$2.70 | $4.77 | $60.7M | -- | $0.00 | 0% | 119.34x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.2M | -- | $0.00 | 0% | 0.33x |
|
VOR
Vor Biopharma, Inc.
|
$13.52 | $44.60 | $92.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
78.76% | -0.363 | 81.25% | 1.03x |
|
IBIO
iBio, Inc.
|
5.55% | 0.486 | 19.65% | 8.21x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
|
VOR
Vor Biopharma, Inc.
|
-0.14% | 23.776 | 0.92% | 9.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
-$904K | -$16.9M | -79.41% | -173.17% | -- | -$9.4M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
VOR
Vor Biopharma, Inc.
|
-$2K | -$28.1M | -- | -- | -- | -$53.9M |
Senti Biosciences, Inc. vs. Competitors
-
Which has Higher Returns SNTI or IBIO?
iBio, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of -5720%. Senti Biosciences, Inc.'s return on equity of -173.17% beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About SNTI or IBIO?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 936.04%. On the other hand iBio, Inc. has an analysts' consensus of $4.77 which suggests that it could grow by 76.54%. Given that Senti Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Senti Biosciences, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 IBIOiBio, Inc.6 0 0 -
Is SNTI or IBIO More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.483%.
-
Which is a Better Dividend Stock SNTI or IBIO?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or IBIO?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of $100K. Senti Biosciences, Inc.'s net income of -$18.1M is lower than iBio, Inc.'s net income of -$5.7M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 119.34x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M IBIOiBio, Inc.119.34x -- $100K -$5.7M
-
Which has Higher Returns SNTI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of -255.85%. Senti Biosciences, Inc.'s return on equity of -173.17% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SNTI or NBY?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 936.04%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Senti Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Senti Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SNTI or NBY More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock SNTI or NBY?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or NBY?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Senti Biosciences, Inc.'s net income of -$18.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns SNTI or PTN?
Palatin Technologies has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SNTI or PTN?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 936.04%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Senti Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Senti Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 PTNPalatin Technologies0 0 0 -
Is SNTI or PTN More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SNTI or PTN?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or PTN?
Senti Biosciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Palatin Technologies's net income of --. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns SNTI or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About SNTI or TOVX?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 936.04%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Senti Biosciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Senti Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is SNTI or TOVX More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock SNTI or TOVX?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or TOVX?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
-
Which has Higher Returns SNTI or VOR?
Vor Biopharma, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Vor Biopharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M VORVor Biopharma, Inc.-- -$121.63 -$2.2B -
What do Analysts Say About SNTI or VOR?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 936.04%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $44.60 which suggests that it could grow by 219.9%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 VORVor Biopharma, Inc.5 1 0 -
Is SNTI or VOR More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SNTI or VOR?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or VOR?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Vor Biopharma, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M VORVor Biopharma, Inc.-- -- -- -$812.7M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
